Mark Kessel Net Worth

The estimated Net Worth of Mark Kessel is at least $30 Million dollars as of 16 October 2012. Mark Kessel owns over 6,000,000 units of Organovo Inc stock worth over $1,666,074 and over the last 20 years Mark sold ONVO stock worth over $28,380,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Kessel ONVO stock SEC Form 4 insiders trading

Mark has made over 1 trades of the Organovo Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Mark sold 6,000,000 units of ONVO stock worth $28,380,000 on 16 October 2012.

The largest trade Mark's ever made was selling 6,000,000 units of Organovo Inc stock on 16 October 2012 worth over $28,380,000. On average, Mark trades about 285,714 units every 0 days since 2004. As of 16 October 2012 Mark still owns at least 3,031,431 units of Organovo Inc stock.

You can see the complete history of Mark Kessel stock trades at the bottom of the page.

What's Mark Kessel's mailing address?

Mark's mailing address filed with the SEC is 6275 NANCY RIDGE DRIVE, SUITE 110, , SAN DIEGO, CA, 92121.

Insiders trading at Organovo Inc

Over the last 13 years, insiders at Organovo Inc have traded over $8,085,375 worth of Organovo Inc stock and bought 386,250 units worth $661,443 . The most active insiders traders include Mark Kessel, Keith Murphy, and Adam K Stern. On average, Organovo Inc executives and independent directors trade stock every 112 days with the average trade being worth of $29,354. The most recent stock trade was executed by David Gobel on 15 November 2023, trading 19,607 units of ONVO stock currently worth $31,763.

What does Organovo Inc do?

organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice.

Complete history of Mark Kessel stock trades at Agenus Inc, Dynavax Technologies, and Organovo Inc

Organovo Inc executives and stock owners

Organovo Inc executives and other stock owners filed with the SEC include:

• Steven Hughes,
  Chief Medical Officer
• Keith Murphy,
  Executive Chairman and Principal Executive Officer
• Steve Kunszabo,
  VP, Investor Relations & Corporate Communications
• Adam Stern,
  Independent Director
• Alison Milhous,
  Independent Director
• David Gobel,
  Independent Director
• Douglas Cohen,
  Independent Director
• Thomas Jurgensen,
  General Counsel
• Jeffrey Miner,
  Chief Scientific Officer
• Chris Heberlig,
  President, Chief Financial Officer
• David Shapiro,
  Director
• Craig Kussman,
  Chief Financial Officer
• Robert Jr. Baltera,
  Director
• Paul Gallant,
  General Manager
• Jennifer Bush,
  General Counsel & Secretary
• Kirk Malloy,
  Director
• Mark Kessel,
  Director
• Taylor Crouch,
  CEO & President
• James T Glover,
  Director
• Sharon Collins Presnell,
  Chief Scientific Officer
• Richard E Maroun,
  Director
• Tamar D Howson,
  Director
• Kevin Kimberlin,
  10% owner
• Richard A. Heyman,
  Director
• Michael Renard,
  EVP of Commercial Operations
• Andras Forgacs,
  Director
• Barry D Michaels,
  Chief Financial Officer
• Eric David,
  CSO & EVP Pre-Clinical Dev
• Carolyn Beaver,
  Director
• Vaidehi Joshi,